Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse

Non-Epithelial Ovarian Cancers: How Much Do We Really Know?

(2022) Alison Cheung et al.   International Journal of Environmental Research and Public Health

Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes

(2022) Sidrah Shah et al.   International Journal of Environmental Research and Public Health

Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer

(2022) Antonios Revythis et al.   International Journal of Environmental Research and Public Health

BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside

(2022) Stergios Boussios et al.   Cancers

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Outcomes of ovarian cancer patients treated with platinum or non-platinum based chemotherapy after PARP inhibitor maintenance.

(2021) Ralynn Brann et al.   JOURNAL OF CLINICAL ONCOLOGY

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations

(2021) Sidrah Shah et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

(2020) Richard T. Penson et al.   JOURNAL OF CLINICAL ONCOLOGY

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

(2020) Heng Zhu et al.   Molecular Cancer

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer

(2020) Michelle McMullen et al.   Cancers

Epithelial ovarian cancer

(2019) Stephanie Lheureux et al.   LANCET

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

(2019) Kathleen N Moore et al.   LANCET ONCOLOGY

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

(2019) Josep M. del Campo et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

(2017) Amit M. Oza et al.   GYNECOLOGIC ONCOLOGY

BRCA1andBRCA2mutations in ovarian cancer patients from China: ethnic-related mutations inBRCA1associated with an increased risk of ovarian cancer

(2017) Tingyan Shi et al.   INTERNATIONAL JOURNAL OF CANCER

The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients

(2017) Xiaohua Wu et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

(2017) Elizabeth M Swisher et al.   LANCET ONCOLOGY

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

(2017) Eric Pujade-Lauraine et al.   LANCET ONCOLOGY

Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status

(2016) Joanne Kotsopoulos et al.   GYNECOLOGIC ONCOLOGY

Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

(2016) Susan M. Domchek et al.   GYNECOLOGIC ONCOLOGY

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

(2015) Sue Richards et al.   GENETICS IN MEDICINE

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

(2015) P. A. Konstantinopoulos et al.   Cancer Discovery

Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

(2013) J. E. Ang et al.   CLINICAL CANCER RESEARCH

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

(2012) L. C. Hanker et al.   ANNALS OF ONCOLOGY

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

(2011) Gordon John Sampson Rustin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials

(2009) Andreas du Bois et al.   CANCER

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results

(2008) Sharon E. Plon et al.   HUMAN MUTATION

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

(2008) David S.P. Tan et al.   JOURNAL OF CLINICAL ONCOLOGY